Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma
|ClinicalTrials.gov Identifier: NCT01366170|
Recruitment Status : Completed
First Posted : June 3, 2011
Last Update Posted : May 19, 2016
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. it may also help doctors predict how patients will respond to treatment.
PURPOSE: This research trial studies biomarker expression in tissue samples from young patients with anaplastic large cell lymphoma.
|Condition or disease||Intervention/treatment|
|Lymphoma||Genetic: microarray analysis Genetic: protein expression analysis Genetic: western blotting Other: flow cytometry Other: immunohistochemistry staining method Other: laboratory biomarker analysis Other: mass spectrometry|
- To determine the expression of immunoregulatory proteins including CD4, FOXP3 and CD276 in anaplastic large cell lymphoma (ALCL).
- To correlate the expression of these proteins with the levels of anaplastic lymphoma kinase (ALK) autoantibodies in patient of ANHL0131.
OUTLINE: Archived tissue microarray samples are analyzed by mass spectrometry and validated by Western blotting, flow cytometry, and IHC.
|Study Type :||Observational|
|Estimated Enrollment :||7 participants|
|Official Title:||Expression of T Immunoregulatory Proteins in ALK+ Anaplastic Large Cell Lymphoma (ALCL)|
|Study Start Date :||May 2011|
|Primary Completion Date :||May 2016|
- Expression of immunoregulatory proteins including CD4, FOXP3 and CD276 in ALCL
- Correlation of CD4, FOXP3, and CD276 with ALK autoantibody response in patients enrolled in ANHL0131
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01366170
|Principal Investigator:||Megan S. Lim, MD, PhD||C.S. Mott Children's Hospital at University of Michigan Medical Center|